New diagnostic approaches in inflammatory bowel disease

Kam, Lori Y.; Vasiliauskas, Eric A.

doi:10.1007/978-1-4020-3477-0_20

Cited by 1 publication

(8 citation statements)

References 126 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Anti-Saccharomyces cerevisiae antibodies (ASCA) are present in 50% to 70% of the sera of patients with CD, and in 6% to 14% of patients with UC; they are rarely expressed in individuals who do not have IBD [8]. This marker is highly specific for CD, particularly for those who express high levels of the IgA and IgG immunoglobulin subtypes of ASCA.…”

Section: Ascamentioning

confidence: 96%

“…Elevated levels of antibodies to Candida albicans, another common yeast, and to other common antigens, such as gliadin, ovalbumin, and betalactoglobulin, have not been observed in CD [15]. Evidence suggests that, as with pANCA, expression of ASCA is not an epiphenomenon of intestinal insult, but rather a reflection of a specific mucosal immune-mediated response [8,16,17]. As with ANCA, familial associations have been observed in patients with ASCA [18,19].…”

Section: Ascamentioning

confidence: 97%

“…Whereas a portion of the discrepancies between studies can be attributed to differences in patient populations, including ethnicity and referral center bias, methodologic differences are likely the biggest factor [8,9]. Although the antigen to which pANCA(s) in IBD react has not been definitively determined, it has been well-characterized, and several lines of evidence support the concept that the pANCAs of CD are the same as the pANCAs of UC [8]. The CD subpopulation expressing pANCA is clinically distinct, having a "UC-like" behavioral phenotype, with clinical features of left-sided colitis and endoscopic or histopathologic features that are typical of UC [7,10••].…”

Section: Pancamentioning

confidence: 97%

“…The reported prevalence of pANCA ranges from 50% to 80% in UC and from 10% to 40% in CD in most series [8]. Whereas a portion of the discrepancies between studies can be attributed to differences in patient populations, including ethnicity and referral center bias, methodologic differences are likely the biggest factor [8,9].…”

Section: Pancamentioning

confidence: 97%

“…Enzymelinked immunosorbent assay (ELISA) levels of sANCA in CD tend to be very low [8]. sANCA has been detected in approximately 14% to 20% of patients with CD; the incidence in UC has not been reported [8,12].…”

Section: Pancamentioning

confidence: 98%

See 4 more Smart Citations

Recent advances in the diagnosis and classification of inflammatory bowel disease

Vasiliauskas

2003

Curr Gastroenterol Rep

View full text Add to dashboard Cite

The availability of an increasing number of inflammatory bowel disease (IBD)-specific serologic antibodies, the discovery of disease-susceptibility genes, the introduction of pharmacogenetic markers, and the recent application of wireless capsule enteroscopy to the evaluation of patients with IBD are providing new types of information that must be integrated with more traditional IBD paradigms. The challenge facing researchers and clinicians is to determine how to incorporate these potentially clinically relevant insights into our understanding of disease pathogenesis and to define the spectrum of potential applications to the management of patients with IBD. The ultimate diagnostic and predictive value of these tests will likely be optimized when they are applied in combination, rather than individually. As the clinical relevance of this expanding diagnostic armamentarium is defined, it is hoped that these tests will enable clinicians not only to diagnose IBD accurately but also to determine disease patterns prospectively, suggest prognoses, and allow for individualization of therapeutic regimens.

show abstract

Section: Ascamentioning

confidence: 96%